Aclaris Therapeutics (ACRS) reported Q4 Revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 Revenue for the quarter came in at $9.21 million versus the consensus estimate of $2.08 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• argenx SE (ARGX) PT Raised to $1,095 at Truist Securities
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance